查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1516707

TCR 疗法的全球市场管道

Global Tcr Therapy Market Pipeline
出版日期: | 出版商: Inkwood Research | 英文 290 Pages | 商品交期: 2-3个工作天内

价格

主要发现

TCR疗法（T细胞受体疗法）是一种创新的免疫疗法，利用人体自身的免疫系统来对抗癌症。在这种方法中，患者的 T 细胞被提取并表达专门设计用于识别并结合肿瘤细胞上 MHC（主要组织相容性复合物）所呈现的癌症相关抗原的受体。

与针对细胞表面抗原的 CAR-T 疗法不同，TCR 疗法可以针对细胞内蛋白质，从而能够针对更广泛的癌症。经过改造后，T 细胞会在实验室中扩增并重新註射到患者体内，在那里它们会寻找并摧毁癌细胞。TCR 疗法在治疗包括实体肿瘤在内的各种癌症方面显示出前景，目前正在进行广泛的研究以优化其疗效和安全性。

市场洞察

全球 TCR 治疗市场成长的主要驱动力

  • 有前途的临床和临床前研究的增加
  • 癌症发生率上升

根据美国癌症协会预测，2023年美国将新增1,958,310例癌症病例，609,820人死亡。癌症发生率的上升凸显了对更有效治疗方法的迫切需要，将 TCR（T 细胞受体）疗法推向了前沿。随着全球癌症发病率飙升，对 TCR 等创新疗法的需求不断增长，这种疗法利用免疫系统来针对癌细胞。

随着越来越多的患者被诊断出患有各种形式的癌症，TCR 疗法的市场自然会扩大，以解决这些不同的适应症。这一趋势证明了 TCR 疗法的多功能性及其满足癌症患者不断变化的需求的潜力，使其成为肿瘤学领域的关键参与者。

随着越来越多的患者需要先进的治疗方案，TCR 疗法专门针对癌细胞的能力使其成为有前景的解决方案。TCR疗法对多种癌症类型的适用性进一步增加了其吸引力，使其成为持续对抗癌症的关键要素，并为癌症治疗提供了充满希望的未来前景。

  • 技术创新和研究活动迅速增加

全球TCR治疗市场的主要成长限制因素

  • TCR 治疗中的细胞激素风暴毒性
  • TCR 基因转殖中的脱靶效应与安全问题
  • 选择最佳标靶抗原的课题

需要适当的 HLA 匹配，因为 T 细胞受体 (TCR) 只能识别肽-HLA 复合物，并且对 HLA 等位基因匹配的癌细胞有效。这意味着非中国来源的TCR-T细胞不能直接应用于中国患者。识别具有最佳亲和力阈值的 TCR 的筛选过程具有课题性，因为需要高亲和力 TCR 来增强免疫反应。

鑑定对抗原具有高亲和力的 TCR 对于有效的免疫反应至关重要，但必须仔细调节这种亲和力。当 TCR 亲和力超过生理极限时，T 细胞可能会受伤。

表达TCR的T细胞辨识抗原的机制对于T细胞免疫至关重要。T 细胞必须对病原体呈现的抗原做出定量反应，同时不对宿主组织上的类似抗原做出反应。

TCR疗法｜概述

  • 介绍
  • TCR的结构特点
  • 预选曲目中的 TCR 多样性

T 细胞受体 (TCR) 的预选库由遗传因子和表观遗传因子共同决定。根据可及性假说，基因片段必须能够被重组机制所访问，其中涉及核重排、DNA甲基化、染色质重塑、组蛋白修饰和种系转录等过程。

最近的分析表明，框架外 TCR-a 序列的频率受到 V 和 J 片段使用的影响，表明存在遗传影响。此外，在胸腺选择之前，重组偏差会促使同基因小鼠的 TCR-B 链库出现显着冗余，突显透过 V(D)J 重组显着塑造 TCR 库组成的倾向。

  • NP 中的 TCR 多样性
  • 健康和疾病中的 TCR 多样性
  • TCR 克隆型作为疾病标记物
  • TCR复合物
  • TCR辅助受体
  • TCR复合体参与T细胞活化的相关分子
  • T细胞受体修饰的T细胞用于癌症治疗：现况与未来方向
  • TCR序列鑑定
  • 改善肿瘤微环境中 TCR 修饰的 T 细胞的功能

竞争考虑

全球 TCR 治疗市场的主要参与者

  • Adaptimmune
  • Gilead Sciences
  • Alaunos Therapeutics
  • Triumvira Immunologics
  • Takara Bio

我们提供 10% 免费客製化和 3 个月的分析师支援。

常见问题（FAQ）：

  • TCR 疗法如何发挥作用？

答：TCR 疗法包括从患者体内提取T 细胞，对它们进行基因改造，使其表达能够识别癌症相关抗原的特定T 细胞受体(TCR)，然后将这些经过修饰的T 细胞注射到患者体内，透过重新接种疫苗来发挥作用。然后，这些经过修饰的 T 细胞会瞄准并杀死表现出特定抗原的癌细胞。

  • TCR 疗法有哪些风险和副作用？

答：TCR 疗法的常见风险和副作用包括细胞激素释放症候群 (CRS)、神经毒性和可能损害健康组织的脱靶效应。这些副作用需要在治疗期间和治疗后仔细监测和管理。

  • TCR疗法和CAR-T疗法有何不同？

答：TCR疗法和CAR-T疗法都是对T细胞进行基因修饰，但其标靶辨识机制不同。CAR-T细胞透过嵌合抗原受体辨识癌细胞上的表面抗原，而TCR疗法则针对MHC分子呈现的细胞内抗原。这使得 TCR 疗法能够靶向更广泛的癌症相关蛋白。

目录

第一章简介

第 2 章 TCR 治疗：概述

第三章概述

  • 介绍
  • TCR的结构特点
  • 预选曲目中的 TCR 多样性
  • NP 中的 TCR 多样性
  • 健康和疾病中 TCR 的多样性
  • TCR 克隆型作为疾病标记物
  • TCR复合物
  • TCR辅助受体
  • TCR复合体参与T细胞活化的相关分子
  • T细胞受体修饰的T细胞用于癌症治疗：现况与未来方向
  • TCR序列的鑑定
  • 改善肿瘤微环境中 TCR 修饰的 T 细胞的功能

第四章市场动态

  • 主要驱动因素
    • 有前途的临床和临床前研究的增加
    • 癌症发生率上升
    • 技术创新和研究活动迅速增加
  • 主要限制因素
    • TCR 治疗中的细胞激素风暴毒性
    • TCR 基因转殖中的脱靶效应与安全问题
    • 选择最佳标靶抗原的课题

第五章管道处理

  • 目前管道概述
  • 比较分析：各阶段产品

第六章治疗评估：有效的产品

  • 依给药途径评价
  • 依阶段和给药途径进行评价
  • 依分子类型评估
  • 依阶段/分子类型评估
  • 依产品类型划分的评级
  • 依阶段/产品类型评估
  • 依治疗区域评估
  • 依阶段/治疗区域进行评估

第七章 后期产品（预先註册）

  • 比较分析
  • ADP-A2M4：ADAPTIMMUNE
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品/开发活动

第八章 后期产品（第三期）

  • 比较分析
  • IMC F106C：IMMUNOCORE
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品/开发活动

第9章：中期产品（II/III期）

  • 比较分析
  • IMC-GP100：IMMUNOCORE
    • 产品描述
    • 研究与开发
    • 产品/开发活动

第10章：中期产品（二期）

  • 比较分析
  • TAEST 16001：GUANGDONG XIANGXUE PRECISION MEDICAL TECHNOLOGY CO LTD
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品/开发活动
  • GSK 3377794：GLAXOSMITHKLINE
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品/开发活动
  • ALT-801：ALTIMMUNE
    • 产品描述
    • 研究与开发
    • 产品/开发活动
  • KITE-439：GILEAD SCIENCES
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品/开发活动
  • KITE-718：GILEAD SCIENCES
    • 产品描述
    • 研究与开发
    • 产品/开发活动

第十一章 早期产品（I/II 期）

  • 比较分析
  • TC-510：ADAPTIMMUNE
    • 产品描述
    • 研究与开发
    • 产品/开发活动
  • TCR-T LIBRARY：ALAUNOS THERAPEUTICS INC
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品/开发活动
  • SCG101：SCG CELL THERAPY
    • 产品描述
    • 研究与开发
    • 安全性/有效性
  • TK-8001：T-KNIFE GMBH
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品/开发活动
  • ECT 204：JW THERAPEUTICS
    • 产品描述
    • 研究与开发
    • 产品/开发活动
  • JWATM 203：JW THERAPEUTICS
    • 产品描述
    • 产品/开发活动
  • IMC I109V：IMMUNOCORE
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品/开发活动
  • IMCM113V：IMMUNOCORE
    • 产品描述
    • 安全性/有效性
    • 产品/开发活动
  • MDG 1011：MEDIGENE AG
    • 产品描述
    • 安全性/有效性
    • 产品/开发活动
  • TC-210：ADAPTIMMUNE THERAPEUTICS
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品/开发活动
  • TC-110：ADAPTIMMUNE THERAPEUTICS
    • 产品描述
    • 研究与开发
    • 安全性/有效性

第十二章产品/开发活动

  • TBI 1301：TAKARA BIO
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品/开发活动
  • IMA402：IMMATICS
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品/开发活动
  • TAC01 HER2：TRIUMVIRA
    • 产品描述
    • 研究与开发
    • 安全性/有效性
  • TAC01 CLDN18.2：TRIUMVIRA
    • 产品描述
    • 研究与开发
    • 安全性/有效性
  • HBV ANTIGEN SPECIFIC TCR REDIRECTED T-CELL：LION TCR
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品/开发活动
  • TC-E202：TCRCURE BIOTECH
    • 产品描述
    • 研究与开发
    • 产品/开发活动

第 13 章早期产品（第一阶段）

  • 比较分析
  • TSC-100：TSCAN THERAPEUTICS
    • 产品描述
    • 研究与开发
    • 安全性/有效性
  • TSC-200：TSCAN THERAPEUTICS
    • 产品描述
    • 研究与开发
  • IMA201：IMMATICS
    • 产品描述
    • 研究与开发
  • IMA203：IMMATICS
    • 产品描述
    • 研究与开发
    • 安全性/有效性
  • ADP-A2M10：ADAPTIMMUNE
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品开发活动
  • ADP-A2AFP：ADAPTIMMUNE
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品开发活动
  • CMV TCR-T：CHINA IMMUNOTECH
    • 产品描述
    • 研究与开发
    • 安全性/有效性
  • IMA401：IMMATICS
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品开发活动
  • BNT221：BIONTECH
    • 产品描述
    • 研究与开发
    • 安全性/有效性
  • NT 125：NEOGENE THERAPEUTICS
    • 产品描述
    • 产品开发活动
  • NT-175：NEOGENE THERAPEUTICS
    • 产品描述
    • 研发内容
    • 产品开发活动
  • LYL-845：LYELL IMMUNOPHARMA
    • 产品描述
    • 研究与开发
  • BRL03：BIOSYNGEN
    • 产品描述
  • TSC 101：TSCAN THERAPEUTICS
    • 产品描述
    • 研究与开发
    • 安全性/有效性
  • AB-1015：ARSENALBIO
    • 产品描述
    • 研究与开发
    • 安全性/有效性
  • TSC 204：TSCAN THERAPEUTICS
    • 产品描述
    • 研究与开发
  • TSC 203：TSCAN THERAPEUTICS
    • 产品描述
    • 产品开发活动
  • 800 TCR：T-CUR
    • 产品描述
    • 研究与开发
    • 产品开发活动
  • 820 TCR：T-CUR
    • 产品描述
    • 研究与开发

第14章 IND阶段的产品

  • 比较分析

第十五章 临床前阶段产品

  • 比较分析

第 16 章发现阶段产品

  • 比较分析

第 17 章非活跃产品

  • 比较分析

第十八章 战略发展

  • 合併/收购
  • 合伙/合约

第19章未满足的需求

Product Code: 90769

KEY FINDINGS

TCR therapy, or T-cell receptor therapy, is an innovative form of immunotherapy that leverages the body's own immune system to combat cancer. This approach involves extracting a patient's T-cells and genetically engineering them to express receptors specifically designed to recognize and bind to cancer-associated antigens presented by the major histocompatibility complex (MHC) on tumor cells.

Unlike CAR-T therapy, which targets antigens on the cell surface, TCR therapy can target intracellular proteins, allowing for a broader range of cancer targets. Once engineered, these T-cells are expanded in the laboratory and reinfused into the patient, where they seek out and destroy cancer cells. TCR therapy holds significant promise for treating various cancers, including solid tumors, and is currently the focus of extensive research to optimize its efficacy and safety.

MARKET INSIGHTS

Key enablers of the global TCR therapy market growth:

  • Growing number of promising clinical and preclinical studies
  • Rising cancer incidence rates

According to the American Cancer Society, the United States is projected to see 1,958,310 new cancer cases and 609,820 cancer deaths in 2023. The rising incidence of cancer underscores the urgent need for more effective treatments, propelling TCR (T-cell receptor) therapy into the forefront. As cancer rates surge globally, the demand for innovative therapies like TCR, which harnesses the immune system to target cancer cells, is increasing.

With more patients being diagnosed with various forms of cancer, the market for TCR therapy naturally expands to address these diverse indications. This trend showcases the versatility of TCR therapy and its potential to meet the evolving needs of cancer patients, positioning it as a significant player in the field of oncology.

As more patients require advanced therapeutic options, TCR therapy's ability to specifically target cancer cells positions it as a promising solution. Its adaptability across different cancer types enhances its appeal, making TCR therapy a crucial component in the ongoing battle against cancer and a key factor in the future landscape of oncology treatments.

  • Surge in innovation and research activities

Key growth restraining factors of the global TCR therapy market:

  • Toxicity from cytokine storms in TCR therapy
  • Off-target effects and safety concerns in TCR gene transfer
  • Challenges in selecting the optimal target antigen

T-cell receptors (TCRs) can only recognize peptide-HLA complexes and are effective against cancer cells that have matching HLA alleles, necessitating appropriate HLA matching. This means that TCR-T-cells derived from non-Chinese individuals cannot be directly applied to Chinese patients. The screening process for identifying TCRs with the optimal affinity threshold is challenging, as high-affinity TCRs are needed to enhance immune responses.

Identifying TCRs with high affinity for antigens is crucial for effective immune responses, but the affinity must be carefully regulated. If TCR affinity exceeds physiological limits, it can result in injury to the T-cells.

The mechanism of antigen recognition by TCR-expressing T-cells is vital for T-cell immunity. T-cells must quantitatively respond to antigens presented by pathogens while remaining unresponsive to similar antigens on host tissues.

TCR Therapy | Overview

  • Introduction
  • Structural characteristics of the TCR
  • TCR diversity in the pre-selection repertoire

The pre-selection repertoire of T-cell receptors (TCRs) is shaped by both genetic and epigenetic factors. According to the accessibility hypothesis, gene segments must be accessible to recombination machinery, involving processes such as subnuclear relocation, DNA methylation, chromatin remodeling, histone modification, and germline transcription.

Although the activation of the 3' proximal region of antigen receptor loci is well understood, the mechanisms controlling the accessibility and activation of the 5' V region remain unclear. Research has shown that V genes in the immunoglobulin heavy chain locus recombine at different frequencies even when they have equal accessibility, implying that similar biases might also be present in TCR loci.

Recent analyses reveal that the frequency of out-of-frame TCR-a sequences is affected by the usage of V and J segments, indicating a genetic influence. Additionally, recombination bias causes a notable overlap in the TCR-B chain repertoire among syngeneic mice before thymic selection, highlighting a predisposition in the TCR repertoire composition that is significantly shaped by V(D)J recombination.

  • TCR diversity in the naive pool
  • TCR diversity in health and disease
  • TCR clonotypes as markers of disease
  • The TCR complex

The TCR receptor complex is an octameric structure with three dimeric signaling modules: CD247 ζ/ζ, CD3δ/ε, and CD3Y/ε, and variable a and B chains. Ionizable residues in the transmembrane domains stabilize the complex, while signaling molecules are essential due to the TCR's short cytoplasmic tail.

TCRs exhibit low affinity for peptide/MHC ligands (dissociation constants of 1-100 μM); but T-cells maintain high antigen specificity and sensitivity through the formation of TCR microclusters, enhancing antigen recognition via an avidity-based mechanism.

Antigen-experienced T-cells (effector and memory) show increased sensitivity and require fewer costimulatory signals and lower antigen concentrations compared to naive T-cells, achieved through functional avidity maturation without changes in affinity.

  • TCR co-receptors
  • Associated molecules of the TCR complex involved in T-cell activation
  • T-cell receptor-engineered T-cells for cancer treatment: Current status and future directions
  • Identification of TCR sequences
  • Improving the function of TCR-engineered T-cells in tumor microenvironment

COMPETITIVE INSIGHTS

Major players in the global TCR therapy market:

  • Adaptimmune
  • Gilead Sciences
  • Alaunos Therapeutics
  • Triumvira Immunologics
  • Takara Bio

Gilead Sciences, a biopharmaceutical company established in 1987 in Foster City, California, specializes in researching, developing, and marketing medicines for life-threatening diseases. With over 7,000 employees spread across offices on six continents, Gilead focuses on therapeutic areas such as HIV/AIDS, hepatitis B and C, influenza, COVID-19, liver diseases, hematology, and oncology. Some of their notable products include Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, and Sunlenca.

KITE-439, developed by Gilead Sciences, is a T lymphocyte replacement therapy. Preclinical studies have shown efficacy with MHC class I-restricted T-cell receptor (TCR)-engineered T-cells targeting the E7 protein on HPV16-positive tumor cells. The drug is currently in Phase II clinical trials for the treatment of both solid and hematological malignancies.

We Offer 10% Free Customization and 3 Months Analyst Support

Frequently Asked Questions (FAQs):

  • How does TCR therapy work?

A: TCR therapy works by extracting T-cells from a patient, genetically engineering them to express specific T-cell receptors (TCRs) that can recognize cancer-associated antigens, and then reinfusing these modified T-cells back into the patient. These engineered T-cells then target and kill cancer cells displaying the specific antigen.

  • What are the risks and side effects of TCR therapy?

A: Common risks and side effects of TCR therapy include cytokine release syndrome (CRS), neurotoxicity, and potential off-target effects that might damage healthy tissues. These side effects necessitate careful monitoring and management during and after treatment.

  • How is TCR therapy different from CAR-T therapy?

A: While both TCR and CAR-T therapies involve genetically modifying T-cells, they differ in their target recognition mechanisms. CAR-T-cells recognize surface antigens on cancer cells through chimeric antigen receptors, whereas TCR therapy targets intracellular antigens presented by MHC molecules. This allows TCR therapy to target a broader range of cancer-associated proteins.

TABLE OF CONTENTS

1. INTRODUCTION TO THE REPORT

2. TCR THERAPY: SUMMARY

3. OVERVIEW

  • 3.1. INTRODUCTION
  • 3.2. STRUCTURAL CHARACTERISTICS OF THE TCR
  • 3.3. TCR DIVERSITY IN THE PRE-SELECTION REPERTOIRE
  • 3.4. TCR DIVERSITY IN THE NAIVE POOL
  • 3.5. TCR DIVERSITY IN HEALTH AND DISEASE
  • 3.6. TCR CLONOTYPES AS MARKERS OF DISEASE
  • 3.7. THE TCR COMPLEX
  • 3.8. TCR CO-RECEPTORS
  • 3.9. ASSOCIATED MOLECULES OF THE TCR COMPLEX INVOLVED IN T-CELL ACTIVATION
  • 3.10. T-CELL RECEPTOR-ENGINEERED T-CELLS FOR CANCER TREATMENT: CURRENT STATUS AND FUTURE DIRECTIONS
  • 3.11. IDENTIFICATION OF TCR SEQUENCES
  • 3.12. IMPROVING THE FUNCTION OF TCR-ENGINEERED T-CELLS IN TUMOR MICROENVIRONMENT

4. MARKET DYNAMICS

  • 4.1. KEY DRIVERS
    • 4.1.1. GROWING NUMBER OF PROMISING CLINICAL AND PRECLINICAL STUDIES
    • 4.1.2. RISING CANCER INCIDENCE RATES
    • 4.1.3. SURGE IN INNOVATION AND RESEARCH ACTIVITIES
  • 4.2. KEY RESTRAINTS
    • 4.2.1. TOXICITY FROM CYTOKINE STORMS IN TCR THERAPY
    • 4.2.2. OFF-TARGET EFFECTS AND SAFETY CONCERNS IN TCR GENE TRANSFER
    • 4.2.3. CHALLENGES IN SELECTING THE OPTIMAL TARGET ANTIGEN

5. PIPELINE THERAPEUTICS

  • 5.1. CURRENT PIPELINE OVERVIEW
  • 5.2. COMPARATIVE ANALYSIS: PRODUCTS IN VARIOUS PHASES

6. THERAPEUTIC ASSESSMENT: ACTIVE PRODUCTS

  • 6.1. EVALUATION BY ROUTE OF ADMINISTRATION
  • 6.2. EVALUATION BY STAGE AND ROUTE OF ADMINISTRATION
  • 6.3. EVALUATION BY MOLECULE TYPE
  • 6.4. EVALUATION BY STAGE AND MOLECULE TYPE
  • 6.5. EVALUATION BY PRODUCT TYPE
  • 6.6. EVALUATION BY STAGE AND PRODUCT TYPE
  • 6.7. EVALUATION BY THERAPY AREA
  • 6.8. EVALUATION BY STAGE AND THERAPY AREA

7. LATE-STAGE PRODUCTS (PRE-REGISTRATION)

  • 7.1. COMPARATIVE ANALYSIS
  • 7.2. ADP-A2M4: ADAPTIMMUNE
    • 7.2.1. PRODUCT DESCRIPTION
    • 7.2.2. RESEARCH AND DEVELOPMENT
    • 7.2.3. SAFETY AND EFFICACY
    • 7.2.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES

8. LATE-STAGE PRODUCTS (PHASE III)

  • 8.1. COMPARATIVE ANALYSIS
  • 8.2. IMC F106C: IMMUNOCORE
    • 8.2.1. PRODUCT DESCRIPTION
    • 8.2.2. RESEARCH AND DEVELOPMENT
    • 8.2.3. SAFETY AND EFFICACY
    • 8.2.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES

9. MID-STAGE PRODUCTS (PHASE II/III)

  • 9.1. COMPARATIVE ANALYSIS
  • 9.2. IMC-GP100: IMMUNOCORE
    • 9.2.1. PRODUCT DESCRIPTION
    • 9.2.2. RESEARCH AND DEVELOPMENT
    • 9.2.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES

10. MID-STAGE PRODUCTS (PHASE II)

  • 10.1. COMPARATIVE ANALYSIS
  • 10.2. TAEST 16001: GUANGDONG XIANGXUE PRECISION MEDICAL TECHNOLOGY CO LTD
    • 10.2.1. PRODUCT DESCRIPTION
    • 10.2.2. RESEARCH AND DEVELOPMENT
    • 10.2.3. SAFETY AND EFFICACY
    • 10.2.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 10.3. GSK 3377794: GLAXOSMITHKLINE
    • 10.3.1. PRODUCT DESCRIPTION
    • 10.3.2. RESEARCH AND DEVELOPMENT
    • 10.3.3. SAFETY AND EFFICACY
    • 10.3.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 10.4. ALT-801: ALTIMMUNE
    • 10.4.1. PRODUCT DESCRIPTION
    • 10.4.2. RESEARCH AND DEVELOPMENT
    • 10.4.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 10.5. KITE-439: GILEAD SCIENCES
    • 10.5.1. PRODUCT DESCRIPTION
    • 10.5.2. RESEARCH AND DEVELOPMENT
    • 10.5.3. SAFETY AND EFFICACY
    • 10.5.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 10.6. KITE-718: GILEAD SCIENCES
    • 10.6.1. PRODUCT DESCRIPTION
    • 10.6.2. RESEARCH AND DEVELOPMENT
    • 10.6.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES

11. EARLY-STAGE PRODUCTS (PHASE I/II)

  • 11.1. COMPARATIVE ANALYSIS
  • 11.2. TC-510: ADAPTIMMUNE
    • 11.2.1. PRODUCT DESCRIPTION
    • 11.2.2. RESEARCH AND DEVELOPMENT
    • 11.2.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.3. TCR-T LIBRARY: ALAUNOS THERAPEUTICS INC
    • 11.3.1. PRODUCT DESCRIPTION
    • 11.3.2. RESEARCH AND DEVELOPMENT
    • 11.3.3. SAFETY AND EFFICACY
    • 11.3.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.4. SCG101: SCG CELL THERAPY
    • 11.4.1. PRODUCT DESCRIPTION
    • 11.4.2. RESEARCH AND DEVELOPMENT
    • 11.4.3. SAFETY AND EFFICACY
  • 11.5. TK-8001: T-KNIFE GMBH
    • 11.5.1. PRODUCT DESCRIPTION
    • 11.5.2. RESEARCH AND DEVELOPMENT
    • 11.5.3. SAFETY AND EFFICACY
    • 11.5.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.6. ECT 204: JW THERAPEUTICS
    • 11.6.1. PRODUCT DESCRIPTION
    • 11.6.2. RESEARCH AND DEVELOPMENT
    • 11.6.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.7. JWATM 203: JW THERAPEUTICS
    • 11.7.1. PRODUCT DESCRIPTION
    • 11.7.2. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.8. IMC I109V: IMMUNOCORE
    • 11.8.1. PRODUCT DESCRIPTION
    • 11.8.2. RESEARCH AND DEVELOPMENT
    • 11.8.3. SAFETY AND EFFICACY
    • 11.8.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.9. IMCM113V: IMMUNOCORE
    • 11.9.1. PRODUCT DESCRIPTION
    • 11.9.2. SAFETY AND EFFICACY
    • 11.9.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.10. MDG 1011: MEDIGENE AG
    • 11.10.1. PRODUCT DESCRIPTION
    • 11.10.2. SAFETY AND EFFICACY
    • 11.10.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.11. TC-210: ADAPTIMMUNE THERAPEUTICS
    • 11.11.1. PRODUCT DESCRIPTION
    • 11.11.2. RESEARCH AND DEVELOPMENT
    • 11.11.3. SAFETY AND EFFICACY
    • 11.11.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.12. TC-110: ADAPTIMMUNE THERAPEUTICS
    • 11.12.1. PRODUCT DESCRIPTION
    • 11.12.2. RESEARCH AND DEVELOPMENT
    • 11.12.3. SAFETY AND EFFICACY

12. PRODUCT AND DEVELOPMENTAL ACTIVITIES

  • 12.1. TBI 1301: TAKARA BIO
    • 12.1.1. PRODUCT DESCRIPTION
    • 12.1.2. RESEARCH AND DEVELOPMENT
    • 12.1.3. SAFETY AND EFFICACY
    • 12.1.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 12.2. IMA402: IMMATICS
    • 12.2.1. PRODUCT DESCRIPTION
    • 12.2.2. RESEARCH AND DEVELOPMENT
    • 12.2.3. SAFETY AND EFFICACY
    • 12.2.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 12.3. TAC01 HER2: TRIUMVIRA
    • 12.3.1. PRODUCT DESCRIPTION
    • 12.3.2. RESEARCH AND DEVELOPMENT
    • 12.3.3. SAFETY AND EFFICACY
  • 12.4. TAC01 CLDN18.2: TRIUMVIRA
    • 12.4.1. PRODUCT DESCRIPTION
    • 12.4.2. RESEARCH AND DEVELOPMENT
    • 12.4.3. SAFETY AND EFFICACY
  • 12.5. HBV ANTIGEN SPECIFIC TCR REDIRECTED T-CELL: LION TCR
    • 12.5.1. PRODUCT DESCRIPTION
    • 12.5.2. RESEARCH AND DEVELOPMENT
    • 12.5.3. SAFETY AND EFFICACY
    • 12.5.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 12.6. TC-E202: TCRCURE BIOTECH
    • 12.6.1. PRODUCT DESCRIPTION
    • 12.6.2. RESEARCH AND DEVELOPMENT
    • 12.6.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES

13. EARLY-STAGE PRODUCTS (PHASE I)

  • 13.1. COMPARATIVE ANALYSIS
  • 13.2. TSC-100: TSCAN THERAPEUTICS
    • 13.2.1. PRODUCT DESCRIPTION
    • 13.2.2. RESEARCH AND DEVELOPMENT
    • 13.2.3. SAFETY AND EFFICACY
  • 13.3. TSC-200: TSCAN THERAPEUTICS
    • 13.3.1. PRODUCT DESCRIPTION
    • 13.3.2. RESEARCH AND DEVELOPMENT
  • 13.4. IMA201: IMMATICS
    • 13.4.1. PRODUCT DESCRIPTION
    • 13.4.2. RESEARCH AND DEVELOPMENT
  • 13.5. IMA203: IMMATICS
    • 13.5.1. PRODUCT DESCRIPTION
    • 13.5.2. RESEARCH AND DEVELOPMENT
    • 13.5.3. SAFETY AND EFFICACY
  • 13.6. ADP-A2M10: ADAPTIMMUNE
    • 13.6.1. PRODUCT DESCRIPTION
    • 13.6.2. RESEARCH AND DEVELOPMENT
    • 13.6.3. SAFETY AND EFFICACY
    • 13.6.4. PRODUCT DEVELOPMENTAL ACTIVITY
  • 13.7. ADP-A2AFP: ADAPTIMMUNE
    • 13.7.1. PRODUCT DESCRIPTION
    • 13.7.2. RESEARCH AND DEVELOPMENT
    • 13.7.3. SAFETY AND EFFICACY
    • 13.7.4. PRODUCT DEVELOPMENTAL ACTIVITY
  • 13.8. CMV TCR-T: CHINA IMMUNOTECH
    • 13.8.1. PRODUCT DESCRIPTION
    • 13.8.2. RESEARCH AND DEVELOPMENT
    • 13.8.3. SAFETY AND EFFICACY
  • 13.9. IMA401: IMMATICS
    • 13.9.1. PRODUCT DESCRIPTION
    • 13.9.2. RESEARCH AND DEVELOPMENT
    • 13.9.3. SAFETY AND EFFICACY
    • 13.9.4. PRODUCT DEVELOPMENTAL ACTIVITIES
  • 13.10. BNT221: BIONTECH
    • 13.10.1. PRODUCT DESCRIPTION
    • 13.10.2. RESEARCH AND DEVELOPMENT
    • 13.10.3. SAFETY AND EFFICACY
  • 13.11. NT 125: NEOGENE THERAPEUTICS
    • 13.11.1. PRODUCT DESCRIPTION
    • 13.11.2. PRODUCT DEVELOPMENTAL ACTIVITIES
  • 13.12. NT-175: NEOGENE THERAPEUTICS
    • 13.12.1. PRODUCT DESCRIPTION
    • 13.12.2. RESEARCH AND DEVELOPMENT
    • 13.12.3. PRODUCT DEVELOPMENTAL ACTIVITIES
  • 13.13. LYL-845: LYELL IMMUNOPHARMA
    • 13.13.1. PRODUCT DESCRIPTION
    • 13.13.2. RESEARCH AND DEVELOPMENT
  • 13.14. BRL03: BIOSYNGEN
    • 13.14.1. PRODUCT DESCRIPTION
  • 13.15. TSC 101: TSCAN THERAPEUTICS
    • 13.15.1. PRODUCT DESCRIPTION
    • 13.15.2. RESEARCH AND DEVELOPMENT
    • 13.15.3. SAFETY AND EFFICACY
  • 13.16. AB-1015: ARSENALBIO
    • 13.16.1. PRODUCT DESCRIPTION
    • 13.16.2. RESEARCH AND DEVELOPMENT
    • 13.16.3. SAFETY AND EFFICACY
  • 13.17. TSC 204: TSCAN THERAPEUTICS
    • 13.17.1. PRODUCT DESCRIPTION
    • 13.17.2. RESEARCH AND DEVELOPMENT
  • 13.18. TSC 203: TSCAN THERAPEUTICS
    • 13.18.1. PRODUCT DESCRIPTION
    • 13.18.2. PRODUCT DEVELOPMENTAL ACTIVITY
  • 13.19. 800 TCR: T-CURE
    • 13.19.1. PRODUCT DESCRIPTION
    • 13.19.2. RESEARCH AND DEVELOPMENT
    • 13.19.3. PRODUCT DEVELOPMENTAL ACTIVITY
  • 13.20. 820 TCR: T-CURE
    • 13.20.1. PRODUCT DESCRIPTION
    • 13.20.2. RESEARCH AND DEVELOPMENT

14. IND-STAGE PRODUCTS

  • 14.1. COMPARATIVE ANALYSIS

15. PRECLINICAL-STAGE PRODUCTS

  • 15.1. COMPARATIVE ANALYSIS

16. DISCOVERY-STAGE PRODUCTS

  • 16.1. COMPARATIVE ANALYSIS

17. INACTIVE PRODUCTS

  • 17.1. COMPARATIVE ANALYSIS

18. STRATEGIC DEVELOPMENTS

  • 18.1. MERGERS & ACQUISITIONS
  • 18.2. PARTNERSHIPS & AGREEMENTS

19. UNMET NEEDS

LIST OF TABLES

  • TABLE 1: TOTAL ACTIVE PRODUCTS IN THE TCR THERAPY PIPELINE
  • TABLE 2: PRODUCTS IN VARIOUS PHASES
  • TABLE 3: EVALUATION BY ROUTE OF ADMINISTRATION
  • TABLE 4: EVALUATION BY MOLECULE TYPE
  • TABLE 5: EVALUATION BY PRODUCT TYPE
  • TABLE 6: EVALUATION BY THERAPY AREA
  • TABLE 7: LATE-STAGE PRODUCTS (PRE-REGISTRATION)
  • TABLE 8: CLINICAL TRIALS DESCRIPTION: ADP-A2M4
  • TABLE 9: GENERAL DESCRIPTION: ADP-A2M4
  • TABLE 10: LATE-STAGE PRODUCTS (PHASE III)
  • TABLE 11: CLINICAL TRIALS DESCRIPTION: IMC-F106C
  • TABLE 12: GENERAL DESCRIPTION: IMC-F106C
  • TABLE 13: MID-STAGE PRODUCTS (PHASE II/III)
  • TABLE 14: CLINICAL TRIALS DESCRIPTION: IMCGP100
  • TABLE 15: GENERAL DESCRIPTION: IMCGP100
  • TABLE 16: MID-STAGE PRODUCTS (PHASE II)
  • TABLE 17: CLINICAL TRIALS DESCRIPTION
  • TABLE 18: GENERAL DESCRIPTION: TAEST 16001
  • TABLE 19: CLINICAL TRIALS DESCRIPTION: GSK 3377794
  • TABLE 20: GENERAL DESCRIPTION: GSK 3377794
  • TABLE 21: CLINICAL TRIALS DESCRIPTION: ALT-801
  • TABLE 22: GENERAL DESCRIPTION: ALT-801
  • TABLE 23: CLINICAL TRIALS DESCRIPTION: KITE-439
  • TABLE 24: GENERAL DESCRIPTION: KITE-439
  • TABLE 25: CLINICAL TRIALS DESCRIPTION: KITE-718
  • TABLE 26: GENERAL DESCRIPTION: KITE-718
  • TABLE 27: EARLY-STAGE PRODUCTS (PHASE I/II)
  • TABLE 28: CLINICAL TRIALS DESCRIPTION: TC-510
  • TABLE 29: GENERAL DESCRIPTION: TC-510
  • TABLE 30: CLINICAL TRIALS DESCRIPTION: TCR-T LIBRARY
  • TABLE 31: GENERAL DESCRIPTION: TCR-T LIBRARY
  • TABLE 32: CLINICAL TRIALS DESCRIPTION: SCG101
  • TABLE 33: GENERAL DESCRIPTION: SCG101
  • TABLE 34: CLINICAL TRIALS DESCRIPTION: TK-8001
  • TABLE 35: GENERAL DESCRIPTION: TK-8001
  • TABLE 36: CLINICAL TRIALS DESCRIPTION: ECT204
  • TABLE 37: GENERAL DESCRIPTION: ECT204
  • TABLE 38: GENERAL DESCRIPTION: JWATM 203
  • TABLE 39: CLINICAL TRIALS DESCRIPTION: IMC-I109V
  • TABLE 40: GENERAL DESCRIPTION: IMC-I109V
  • TABLE 41: GENERAL DESCRIPTION: IMC M113V
  • TABLE 42: GENERAL DESCRIPTION: MDG 1011
  • TABLE 43: CLINICAL TRIALS DESCRIPTION: TC-210
  • TABLE 44: GENERAL DESCRIPTION: TC-210
  • TABLE 45: CLINICAL TRIALS DESCRIPTION: TC-110
  • TABLE 46: GENERAL DESCRIPTION: TC-110
  • TABLE 47: CLINICAL TRIALS DESCRIPTION: TBI 1301
  • TABLE 48: GENERAL DESCRIPTION: TBI 1301
  • TABLE 49: CLINICAL TRIALS DESCRIPTION: IMA402
  • TABLE 50: GENERAL DESCRIPTION: IMA402
  • TABLE 51: CLINICAL TRIALS DESCRIPTION: TAC01 HER2
  • TABLE 52: GENERAL DESCRIPTION: TAC01 HER2
  • TABLE 53: CLINICAL TRIALS DESCRIPTION: TAC01 CLDN18.2
  • TABLE 54: GENERAL DESCRIPTION: TAC01 CLDN18.2
  • TABLE 55: CLINICAL TRIALS DESCRIPTION: HBV ANTIGEN SPECIFIC TCR REDIRECTED T-CELL
  • TABLE 56: GENERAL DESCRIPTION: HBV ANTIGEN SPECIFIC TCR REDIRECTED T-CELL
  • TABLE 57: CLINICAL TRIALS DESCRIPTION: TC-E202
  • TABLE 58: GENERAL DESCRIPTION: TC-E202
  • TABLE 59: EARLY-STAGE PRODUCTS (PHASE I)
  • TABLE 60: CLINICAL TRIALS DESCRIPTION: TSC-100
  • TABLE 61: GENERAL DESCRIPTION: TSC-100
  • TABLE 62: CLINICAL TRIALS DESCRIPTION: TSC-200
  • TABLE 63: GENERAL DESCRIPTION: TSC-200
  • TABLE 64: CLINICAL TRIALS DESCRIPTION: IMA201
  • TABLE 65: GENERAL DESCRIPTION: IMA201
  • TABLE 66: CLINICAL TRIALS DESCRIPTION: IMA203
  • TABLE 67: GENERAL DESCRIPTION: IMA203
  • TABLE 68: CLINICAL TRIALS DESCRIPTION: ADP-A2M10
  • TABLE 69: GENERAL DESCRIPTION: ADP-A2M10
  • TABLE 70: CLINICAL TRIALS DESCRIPTION: ADP-A2AFP
  • TABLE 71: GENERAL DESCRIPTION: ADP-A2AFP
  • TABLE 72: CLINICAL TRIALS DESCRIPTION: CMV-TCR-T
  • TABLE 73: GENERAL DESCRIPTION: CMV-TCR-T
  • TABLE 74: CLINICAL TRIALS DESCRIPTION: IMA401
  • TABLE 75: GENERAL DESCRIPTION: IMA401
  • TABLE 76: CLINICAL TRIALS DESCRIPTION: BNT221
  • TABLE 77: GENERAL DESCRIPTION: BNT221
  • TABLE 78: GENERAL DESCRIPTION: NT-125
  • TABLE 79: CLINICAL TRIALS DESCRIPTION: NT-175
  • TABLE 80: GENERAL DESCRIPTION: NT-175
  • TABLE 81: CLINICAL TRIALS DESCRIPTION: LYL845
  • TABLE 82: GENERAL DESCRIPTION: LYL845
  • TABLE 83: GENERAL DESCRIPTION: BRL03
  • TABLE 84: CLINICAL TRIALS DESCRIPTION: TSC-101
  • TABLE 85: GENERAL DESCRIPTION: TSC-101
  • TABLE 86: CLINICAL TRIALS DESCRIPTION: AB-1015
  • TABLE 87: GENERAL DESCRIPTION: AB-1015
  • TABLE 88: CLINICAL TRIALS DESCRIPTION: TSC-204
  • TABLE 89: GENERAL DESCRIPTION: TSC-204
  • TABLE 90: GENERAL DESCRIPTION: TSC-203
  • TABLE 91: CLINICAL TRIALS DESCRIPTION: 800 TCR
  • TABLE 92: GENERAL DESCRIPTION: 800 TCR
  • TABLE 93: CLINICAL TRIALS DESCRIPTION: 820 TCR
  • TABLE 94: GENERAL DESCRIPTION: 820 TCR
  • TABLE 95: IND-STAGE PRODUCTS
  • TABLE 96: PRECLINICAL-STAGE PRODUCTS
  • TABLE 97: DISCOVERY-STAGE PRODUCTS
  • TABLE 98: INACTIVE-STAGE PRODUCTS
  • TABLE 99: LIST OF MERGERS & ACQUISITIONS
  • TABLE 100: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES

  • FIGURE 1: TCR PROTEIN AND GENE STRUCTURE
  • FIGURE 2: GENE REARRANGEMENT AT THE TR LOCI
  • FIGURE 3: SIZE AND COMPOSITION OF THE PRE-SELECTION, NAIVE AND ANTIGEN-EXPERIENCED REPERTOIRES
  • FIGURE 4: SKEWING OF THE TCR REPERTOIRE IN HUMAN DISEASE
  • FIGURE 5: PROCESS OF TCR-ENGINEERED T-CELLS THERAPY
  • FIGURE 6: TCR SIGNALING
  • FIGURE 7: THREE TYPICAL PROCEDURES TO OBTAIN TCR SEQUENCE
  • FIGURE 8: PRODUCTS IN VARIOUS PHASES
  • FIGURE 9: EVALUATION BY ROUTE OF ADMINISTRATION
  • FIGURE 10: EVALUATION BY STAGE AND ROUTE OF ADMINISTRATION
  • FIGURE 11: EVALUATION BY MOLECULE TYPE
  • FIGURE 12: EVALUATION BY STAGE AND MOLECULE TYPE
  • FIGURE 13: EVALUATION BY PRODUCT TYPE
  • FIGURE 14: EVALUATION BY STAGE AND PRODUCT TYPE
  • FIGURE 15: EVALUATION BY THERAPY AREA
  • FIGURE 16: EVALUATION BY STAGE AND THERAPY AREA
  • FIGURE 17: LATE-STAGE PRODUCTS (PRE-REGISTRATION)
  • FIGURE 18: LATE-STAGE PRODUCTS (PHASE III)
  • FIGURE 19: MID-STAGE PRODUCTS (PHASE II/III)
  • FIGURE 20: MID-STAGE PRODUCTS (PHASE II)
  • FIGURE 21: EARLY-STAGE PRODUCTS (PHASE I/II)
  • FIGURE 22: EARLY-STAGE PRODUCTS (PHASE I)
  • FIGURE 23: IND-STAGE PRODUCTS
  • FIGURE 24: PRECLINICAL-STAGE PRODUCTS
  • FIGURE 25: DISCOVERY-STAGE PRODUCTS
  • FIGURE 26: INACTIVE STAGE PRODUCTS